97 related articles for article (PubMed ID: 8113972)
1. Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat.
Mathôt RA; van Schaick EA; Langemeijer MW; Soudijn W; Breimer DD; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1994 Feb; 268(2):616-24. PubMed ID: 8113972
[TBL] [Abstract][Full Text] [Related]
2. Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats.
van Schaick EA; Tukker HE; Roelen HC; IJzerman AP; Danhof M
Br J Pharmacol; 1998 Jun; 124(3):607-18. PubMed ID: 9647488
[TBL] [Abstract][Full Text] [Related]
3. 8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo.
Van Schaick EA; Math-ot RA; Gubbens-Stibbe JM; Langemeijer MW; Roelen HC; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1997 Nov; 283(2):800-8. PubMed ID: 9353401
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-phenylisopropyladenosine in conscious normotensive rats.
Mathôt RA; Van den Aarsen BC; Soudijn W; Breimer DD; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1995 Apr; 273(1):405-14. PubMed ID: 7714796
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors.
Van Der Graaf PH; Van Schaick EA; Math-ot RA; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1997 Nov; 283(2):809-16. PubMed ID: 9353402
[TBL] [Abstract][Full Text] [Related]
6. Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo.
Mathot RA; Wenden EM; Soudijn W; Breimer DD; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1996 Dec; 279(3):1439-46. PubMed ID: 8968369
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats.
van Schaick EA; de Greef HJ; Langemeijer MW; Sheehan MJ; IJzerman AP; Danhof M
Br J Pharmacol; 1997 Oct; 122(3):525-33. PubMed ID: 9351510
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo.
Van der Graaf PH; Van Schaick EA; Visser SA; De Greef HJ; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1999 Aug; 290(2):702-9. PubMed ID: 10411581
[TBL] [Abstract][Full Text] [Related]
9. Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline.
Appel S; Mathôt RA; Langemeijer MW; IJzerman AP; Danhof M
Br J Pharmacol; 1995 Aug; 115(7):1253-9. PubMed ID: 7582553
[TBL] [Abstract][Full Text] [Related]
10. Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling.
Van der Graaf PH; Danhof M
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):442-6. PubMed ID: 9352393
[TBL] [Abstract][Full Text] [Related]
11. Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo.
Mathôt RA; Van der Wenden EM; Soudijn W; IJzerman AP; Danhof M
Br J Pharmacol; 1995 Oct; 116(3):1957-64. PubMed ID: 8640332
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain.
Schaddelee MP; Collins SD; DeJongh J; de Boer AG; Ijzerman AP; Danhof M
Eur J Pharmacol; 2005 May; 514(2-3):131-40. PubMed ID: 15910799
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic characterization of the cardiovascular, hypnotic, EEG and ventilatory responses to dexmedetomidine in the rat.
Bol CJJG ; Danhof M; Stanski DR; Mandema JW
J Pharmacol Exp Ther; 1997 Dec; 283(3):1051-8. PubMed ID: 9399976
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic modelling of the haemodynamic effects of the A2a adenosine receptor agonist CGS 21680C in conscious normotensive rats.
Mathôt RA; Cleton A; Soudijn W; IJzerman AP; Danhof M
Br J Pharmacol; 1995 Feb; 114(4):761-8. PubMed ID: 7773536
[TBL] [Abstract][Full Text] [Related]
15. Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects.
van Schaick EA; Kulkarni C; von Frijtag Drabbe Künzel JK; Mathôt RA; Cristalli G; IJzerman AP; Danhof M
Naunyn Schmiedebergs Arch Pharmacol; 1997 Dec; 356(6):827-37. PubMed ID: 9453470
[TBL] [Abstract][Full Text] [Related]
16. Negative chronotropic response to adenosine receptor stimulation in rat right atria after run training.
Priviero F; De Nucci G; Antunes E; Zanesco A
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):741-3. PubMed ID: 15554918
[TBL] [Abstract][Full Text] [Related]
17. Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action.
van Schaick EA; Zuideveld KP; Tukker HE; Langemeijer MW; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1998 Oct; 287(1):21-30. PubMed ID: 9765317
[TBL] [Abstract][Full Text] [Related]
18. The antinociceptive effects of the systemic adenosine A1 receptor agonist CPA in the absence and in the presence of spinal cord sensitization.
Curros-Criado MM; Herrero JF
Pharmacol Biochem Behav; 2005 Dec; 82(4):721-6. PubMed ID: 16403570
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation.
Cox EH; Kuipers JA; Danhof M
Br J Pharmacol; 1998 Aug; 124(7):1534-40. PubMed ID: 9723968
[TBL] [Abstract][Full Text] [Related]
20. Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid.
Dhalla AK; Santikul M; Smith M; Wong MY; Shryock JC; Belardinelli L
J Pharmacol Exp Ther; 2007 Apr; 321(1):327-33. PubMed ID: 17204748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
